Johnson & Johnson reported first-quarter 2026 financial results that exceeded Wall Street’s expectations, driven by its innovative medicine division which generated over $15 billion in sales—an 11% increase compared to the same period in 2025. This robust performance comes as the company successfully navigates the loss of exclusivity for its former blockbuster.
Shifts in Product Portfolio:
-
Successor Strategies: While Stelara faces increasing pressure from biosimilar competition, J&J has found a strong successor in Tremfya. The newer autoimmune treatment posted a 74% increase in sales, reaching $1.6 billion in the first quarter alone following expanded approvals for inflammatory bowel diseases.
-
Oncology Dominance: The company’s multiple myeloma franchise has become a steady counterweight to immunology losses. Darzalex recorded nearly $4 billion in quarterly sales, while newer therapies like the cell treatment Carvykti and bispecific antibodies Tecvayli and Talvey contributed roughly $5 billion to the total revenue.
-
Future Guidance: Based on early 2026 momentum, J&J slightly raised its annual sales guidance to surpass $100 billion. Executives pointed to the recent launch of the psoriasis pill Icotyde as a key driver for long-term growth.
Despite the strong top-line growth, net profit for the quarter fell by more than half to just over $5 billion, reflecting significant operational shifts and investments. Nevertheless, J&J remains confident in its path to achieve double-digit sales growth across its pharmaceutical and medical device businesses through the end of the decade.